abstract |
The present invention relates to DGAT-1 inhibitor compounds of formula (I), pharmaceutically acceptable salts and prodrugs thereof, and pharmaceutical compositions, methods for their preparation and their use, for example in the treatment of obesity. Formula I In the above formula, for example Ring A is optionally substituted 2,6-pyrazindiyl; X is = O; Ring B is optionally substituted 1,4-phenylene; Y 1 is a direct bond or -O-; Y 2 is-(CH 2 ) r -wherein r is 2 or 3; n is 0, or when Y 1 is a direct bond between ring B and ring C, ring B is 1,4-phenylene and ring C is (4-6C) cycloalkane, n is 1; Ring C is optionally substituted (4-6C) cycloalkane, (7-10C) bicycloalkane, (8-12C) tricycloalkane, phenylene or pyridinediyl; L is a direct bond or -O-; p is 0, 1 or 2, and when p is 1 or 2, R A1 and R A2 are each independently hydrogen or (1-4C) alkyl; Z is carboxy or an analog or bioploidy thereof. |